Higher rates of valvular heart disease
In Latin America, valvular heart diseases remain a major healthcare concern, driven by both rheumatic and degenerative causes. Rheumatic heart disease continues to affect younger populations in countries such as Brazil, Mexico, and Argentina, while aging populations are experiencing more cases of aortic and mitral valve degeneration. Improved awareness and diagnostic access in urban centers are uncovering more cases that previously went undetected, increasing demand for advanced treatment options. Hospitals in major cities are seeing a growing number of patients requiring intervention for moderate to severe valve dysfunction.
Traditional open-heart surgery is often challenging in the region due to uneven distribution of cardiac centers and limited surgical capacity in rural areas. Many patients face travel, cost, and procedural risk barriers that make surgery difficult. Minimally invasive transcatheter heart valve therapies provide an alternative that is safer for high-risk patients and more feasible for hospitals with catheterization labs rather than full surgical facilities. This is encouraging cardiologists to consider these procedures more frequently, especially for older patients or those with multiple health conditions.
Public and private health initiatives in Latin America are beginning to emphasize minimally invasive cardiac care. Training programs for interventional cardiologists, partnerships with device manufacturers, and awareness campaigns are helping improve access to transcatheter procedures. As more patients are diagnosed earlier and referred for less invasive treatment, the rising prevalence of valvular heart disease is driving the adoption of transcatheter heart valves across Latin America.
Expansion of mitral and tricuspid THV use
Although aortic valve interventions have historically, there is a growing clinical focus on mitral and tricuspid valve disorders in Latin America. Improved echocardiography and cardiac imaging have enabled physicians to identify these conditions more reliably, while specialized training is allowing cardiologists to perform transcatheter interventions for patients who were previously ineligible for surgery. Hospitals in urban centers such as São Paulo, Buenos Aires, and Mexico City are expanding their procedures to include these valves, creating a significant opportunity for market growth.
Patients with mitral and tricuspid valve disease are often older or have other health conditions, making traditional surgery risky. Transcatheter therapies offer a minimally invasive solution that shortens recovery time and reduces complications. In a region where healthcare access can be uneven, these therapies allow more patients to receive timely care in well-equipped centers without the burden of extensive hospitalization.
For device companies and healthcare providers, this represents a clear opportunity to expand the market. Providing clinical training, procedural support, and educational programs can help local physicians adopt these advanced techniques. As clinical confidence grows and awareness increases among patients, mitral and tricuspid valve applications are expected to become a key growth segment in Latin America's transcatheter heart valve market.
